Delving into the Latest Updates on Fazamorexant with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

OX1R x OX2R

Mechanism

OX1R antagonists(Orexin receptor type 1 antagonists), OX2R antagonists(Orexin receptor type 2 antagonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Sleep Initiation and Maintenance DisordersCentral Nervous System Diseases

Inactive Indication-

Originator Organization

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

Active Organization

Shanghai Haiyan Pharmaceutical Technology Co Ltd

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

RegulationSpecial Review Project (CN)

Login to view timeline

Structure

Molecular FormulaC25H25FN4O2

InChIKeyPMJPLAGTPPVSRL-JLMWRMLUSA-N

CAS Registry1808918-69-5

Primary Objective：
1) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; To observe the safety of YZJ-1139 tablets taken together with Escitalopram oxalate tablets.

Start Date31 Aug 2024

Sponsor / Collaborator

Shanghai Haiyan Pharmaceutical Technology Co Ltd

CTR20242936 / Active, not recruitingPhase 1

YZJ-1139片与草酸艾司西酞普兰片的药物相互作用研究

[Translation] Study on drug interaction between YZJ-1139 tablets and escitalopram oxalate tablets

主要目的：评价健康受试者口服YZJ-1139片与草酸艾司西酞普兰片的药效学相互作用；次要目的：评价健康受试者口服YZJ-1139片与草酸艾司西酞普兰片的药代动力学相互作用；观察YZJ-1139片与草酸艾司西酞普兰片同服的安全性。

[Translation]

Primary objective: To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and escitalopram oxalate tablets in healthy subjects; Secondary objective: To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and escitalopram oxalate tablets in healthy subjects; To observe the safety of taking YZJ-1139 tablets and escitalopram oxalate tablets together.

Start Date26 Aug 2024

Sponsor / Collaborator

Yangtze River Pharmacy Group Jiangsu Haici Biological Pharmacy

[+2]

NCT06671470 / Active, not recruitingPhase 1

Drug Interaction Study of YZJ-1139 Tablets With Ticagrelor Tablets

Primary Objective :
To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects;
Secondary Objective:
To evaluate the safety of ticagrelor tablets in combination with YZJ-1139 tablets in healthy subjects.

Start Date22 Aug 2024

Sponsor / Collaborator

Shanghai Haiyan Pharmaceutical Technology Co Ltd

100 Clinical Results associated with Fazamorexant

Login to view more data

100 Translational Medicine associated with Fazamorexant

Login to view more data

100 Patents (Medical) associated with Fazamorexant

Login to view more data

100 Deals associated with Fazamorexant

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	Phase 3	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	17 Dec 2021
Central Nervous System Diseases	Phase 1	CN	Shanghai Haiyan Pharmaceutical Technology Co Ltd	31 Aug 2024